CORVUS PHARMACEUTICALS INC (CRVS) Fundamental Analysis & Valuation

NASDAQ:CRVS • US2210151005

Current stock price

15.19 USD
+0.77 (+5.34%)
At close:
15.19 USD
0 (0%)
Pre-Market:

This CRVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRVS Profitability Analysis

1.1 Basic Checks

  • CRVS had negative earnings in the past year.
  • In the past year CRVS has reported a negative cash flow from operations.
  • CRVS had negative earnings in each of the past 5 years.
  • CRVS had a negative operating cash flow in each of the past 5 years.
CRVS Yearly Net Income VS EBIT VS OCF VS FCFCRVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • CRVS has a Return On Assets of -21.49%. This is in the better half of the industry: CRVS outperforms 74.37% of its industry peers.
  • CRVS has a better Return On Equity (-24.97%) than 78.45% of its industry peers.
Industry RankSector Rank
ROA -21.49%
ROE -24.97%
ROIC N/A
ROA(3y)-57.08%
ROA(5y)-54.26%
ROE(3y)-95.37%
ROE(5y)-80.85%
ROIC(3y)N/A
ROIC(5y)N/A
CRVS Yearly ROA, ROE, ROICCRVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVS Yearly Profit, Operating, Gross MarginsCRVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CRVS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CRVS has more shares outstanding
  • The number of shares outstanding for CRVS has been increased compared to 5 years ago.
  • There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVS Yearly Shares OutstandingCRVS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CRVS Yearly Total Debt VS Total AssetsCRVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • An Altman-Z score of 67.93 indicates that CRVS is not in any danger for bankruptcy at the moment.
  • CRVS has a Altman-Z score of 67.93. This is amongst the best in the industry. CRVS outperforms 96.70% of its industry peers.
  • There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 67.93
ROIC/WACCN/A
WACCN/A
CRVS Yearly LT Debt VS Equity VS FCFCRVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 6.21 indicates that CRVS has no problem at all paying its short term obligations.
  • The Current ratio of CRVS (6.21) is better than 63.30% of its industry peers.
  • CRVS has a Quick Ratio of 6.21. This indicates that CRVS is financially healthy and has no problem in meeting its short term obligations.
  • CRVS has a better Quick ratio (6.21) than 63.50% of its industry peers.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
CRVS Yearly Current Assets VS Current LiabilitesCRVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRVS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 82.98% over the past year.
EPS 1Y (TTM)82.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CRVS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.69% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-342.97%
EPS Next 2Y-122.52%
EPS Next 3Y-68.47%
EPS Next 5Y28.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRVS Yearly Revenue VS EstimatesCRVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
CRVS Yearly EPS VS EstimatesCRVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRVS Valuation Analysis

4.1 Price/Earnings Ratio

  • CRVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVS Price Earnings VS Forward Price EarningsCRVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVS Per share dataCRVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • CRVS's earnings are expected to decrease with -68.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-122.52%
EPS Next 3Y-68.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRVS Dividend Analysis

5.1 Amount

  • No dividends for CRVS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRVS Fundamentals: All Metrics, Ratios and Statistics

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (4/30/2026, 8:00:02 PM)

Premarket: 15.19 0 (0%)

15.19

+0.77 (+5.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners42.08%
Inst Owner Change0.12%
Ins Owners3.76%
Ins Owner Change6.84%
Market Cap1.28B
Revenue(TTM)N/A
Net Income(TTM)-15.28M
Analysts86.15
Price Target35.87 (136.14%)
Short Float %24.78%
Short Ratio13.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.96%
Min EPS beat(2)-13.74%
Max EPS beat(2)11.83%
EPS beat(4)3
Avg EPS beat(4)75.31%
Min EPS beat(4)-13.74%
Max EPS beat(4)273.3%
EPS beat(8)5
Avg EPS beat(8)-10.37%
EPS beat(12)7
Avg EPS beat(12)-8.28%
EPS beat(16)9
Avg EPS beat(16)-12.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.48%
PT rev (3m)129.35%
EPS NQ rev (1m)0.72%
EPS NQ rev (3m)-6.5%
EPS NY rev (1m)-15.18%
EPS NY rev (3m)-20.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.84
P/tB 20.84
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -21.49%
ROE -24.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.08%
ROA(5y)-54.26%
ROE(3y)-95.37%
ROE(5y)-80.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 165.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z 67.93
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y-342.97%
EPS Next 2Y-122.52%
EPS Next 3Y-68.47%
EPS Next 5Y28.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.24%
EBIT Next 3Y-22.38%
EBIT Next 5Y49.78%
FCF growth 1Y-29.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29%
OCF growth 3YN/A
OCF growth 5YN/A

CORVUS PHARMACEUTICALS INC / CRVS Fundamental Analysis FAQ

What is the fundamental rating for CRVS stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRVS.


What is the valuation status of CORVUS PHARMACEUTICALS INC (CRVS) stock?

ChartMill assigns a valuation rating of 0 / 10 to CORVUS PHARMACEUTICALS INC (CRVS). This can be considered as Overvalued.


What is the profitability of CRVS stock?

CORVUS PHARMACEUTICALS INC (CRVS) has a profitability rating of 1 / 10.


What is the financial health of CORVUS PHARMACEUTICALS INC (CRVS) stock?

The financial health rating of CORVUS PHARMACEUTICALS INC (CRVS) is 8 / 10.